Evidence map›Paper›PMID 32814635›Full record

Observational studyMedicina clinica2020

[Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group].

Saioa Zalba Marcos, María Luisa Antelo, Arkaitz Galbete, Maialen Etayo, Eva Ongay, José Antonio García-Erce

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in Medicina clinica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 14 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Saioa Zalba MarcosServicio de Hematología y Hemoterapia, Complejo Hospitalario de Navarra, Pamplona, Navarra, España.
María Luisa AnteloServicio de Apoyo a la Gestión Clínica y Continuidad Asistencial, Complejo Hospitalario de Navarra, Pamplona, Navarra, España.
Arkaitz GalbeteNavarrabiomed-Complejo Hospitalario de Navarra-UPNA, IDISNA, REDISSEC, Pamplona, Navarra, España.
Maialen EtayoServicio de Hematología y Hemoterapia, Complejo Hospitalario de Navarra, Pamplona, Navarra, España.
Eva OngayServicio de Análisis Clínicos, Hospital García Orcoyen, Estella-Lizarra, Navarra, España.
José Antonio García-ErceBanco de Sangre y Tejidos de Navarra, Servicio Navarro de Salud, Osasunbidea, Pamplona, Navarra, España; Grupo Español de Rehabilitación Multimodal (GERM), Instituto Aragonés de Ciencias de la Salud, Zaragoza, España; Grupo idiPAZ de «Investigación en PBM», Madrid, España. Electronic address: ja.garcia.erce@navarra.es.
Complejo Hospitalario de Navarra · ESServicio Navarro de Salud · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV-2 infection is clinically very heterogeneous, varying from asymptomatic to severe clinical conditions with a fatal outcome. Some studies suggests that the ABO blood group could be a biological marker of susceptibility for the development of the disease. PATIENTS AND

methodsWe collected data from patients admitted with COVID-19 infection who had ABO blood group recorded, and analyzed the incidence by groups, compared with the global population in Navarre, as well as their main complications and evolution.

resultsGroup O was proportionally less represented in the hospitalized patients with respect to the global population, although the difference was not statistically significant. Group B had significantly higher rates of thrombotic complications and required more admissions in intensive care units.

conclusionThe study suggests a lower susceptibility to infection in group O and a higher risk of complications in group B. Studies with a larger sample size are required in order to obtain significant results.

Indexed as

ABO Blood-Group SystemBetacoronavirusAdultAgedAged, 80 and overBiomarkersCoronavirus InfectionsCOVID-19FemaleHumansLogistic ModelsMaleMiddle AgedPandemicsPneumonia, ViralRetrospective StudiesABO Blood-Group SystemBiomarkersBlood groups ABOCoronavirusCOVID-19Factor de von WillebrandFactores de riesgoGrupos sanguíneos ABORisk factorsSARS-CoV-2Von Willebrand factor

Identifiers

PMID32814635
PMCPMC7346773
OpenAlexW3041342668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.